Related Experiment Video
Updated: Aug 23, 2026
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues
Dorothea Weckermann1, Rolf Harzmann
1Department of Urology, Klinikum Augsburg, Stenglinstr. 2, 86156, Germany. dorothea.weckermann@uro.augsburg-med.de
Abstract:
GnRH agonists have a proven and well-established role in the management of prostate cancer. Further adaptations of the amino-acid sequence led to the development of antagonists with potential therapeutic uses, including a possible role in prostate cancer patients. Treatment of prostate cancer with GnRH agonists results in an initial flare of symptoms that may be prevented by co-administration of a steroidal or non-steroidal antiandrogen. However, this can be associated with additional adverse effects. Clinical studies have shown that GnRH antagonists produce a rapid decline in testosterone but without the disease flare. However these short-term effects have yet to be proven to lead to long-term survival benefits. There have been some reports that antagonists may be associated with adverse effects due to histamine release leading to severe allergic reactions. GnRH agonists are currently available in a range of depot formulations, allowing treatment to be tailored to the patient's needs. At present, the antagonists are only available as on-month depot formulations, which may limit their clinical use. Abarelix should be given intramuscularly. It is the first GnRH antagonist which is approved by the FDA for patients with advanced prostate cancer who should be treated under a risk management program. In Europe, abarelix has not been registered yet.
Insights
Gonadotropin-releasing hormone (GnRH) antagonists offer rapid testosterone reduction without the initial flare seen with GnRH agonists, but long-term survival benefits require further study. Current antagonist formulations may limit clinical use compared to established agonist options.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Gonadotropin-releasing hormone (GnRH) agonists are established treatments for prostate cancer, but can cause an initial symptom flare.
- GnRH antagonists have been developed as an alternative therapeutic option.
- Prostate cancer management requires effective hormonal therapies with manageable side effect profiles.
Purpose of the Study:
- To compare the efficacy and safety of GnRH antagonists versus GnRH agonists in prostate cancer management.
- To evaluate the potential advantages of GnRH antagonists, such as the absence of a disease flare.
- To assess the long-term outcomes and adverse event profiles associated with GnRH antagonists.
Main Methods:
- Review of clinical studies investigating GnRH agonists and antagonists in prostate cancer.
- Analysis of testosterone level changes, disease flare incidence, and survival data.
- Evaluation of adverse events, including histamine release and allergic reactions.
Main Results:
- GnRH antagonists induce a rapid decline in testosterone levels without the initial disease flare associated with GnRH agonists.
- Long-term survival benefits of GnRH antagonists have not yet been established.
- Adverse effects of GnRH antagonists, such as histamine release, have been reported.
- GnRH agonists offer various depot formulations, while antagonists are currently limited to on-month depots.
- Abarelix, a GnRH antagonist, is FDA-approved for advanced prostate cancer under a risk management program.
Conclusions:
- GnRH antagonists provide a rapid testosterone suppression without disease flare, offering a potential alternative to GnRH agonists.
- Further research is needed to confirm long-term survival benefits and fully characterize the safety profile of GnRH antagonists.
- Formulation limitations of current GnRH antagonists may impact their widespread clinical adoption compared to GnRH agonists.
Related Concept Videos
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:22Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
01:25Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.